Literature DB >> 7960107

Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity.

E E Moran1, B L Brandt, W D Zollinger.   

Abstract

The influence of lipopolysaccharide (LPS) expression on the sensitivity of Neisseria meningitidis to serum bactericidal activity was investigated by using a series of variants that expressed different LPS determinants. For each of two different strains, a series of three LPS variants that expressed L3,7, L8, or both were analyzed. LPS variants were identified and monitored by colony blotting with murine monoclonal antibodies specific for the L8 or the L3,7,9 immunotype determinants. Differences in LPS expression were verified by analysis of proteinase K lysates of whole cells by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then by silver staining or immunoblotting. The variants were used as test strains in bactericidal assays with human sera and with murine sera and monoclonal antibodies. Expression of the L8 LPS epitope was correlated with increased sensitivity to serum bactericidal activity. The geometric mean bactericidal titers of 12 to 16 sets of pre- and postvaccination sera were determined for each variant. Mean serum titers increased progressively with increased expression of L8 on the target strain. The bactericidal titers of anti-outer membrane protein monoclonal antibodies also increased with increased L8 expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7960107      PMCID: PMC303267          DOI: 10.1128/iai.62.12.5290-5295.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.

Authors:  G A Jarvis; N A Vedros
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

2.  Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharides.

Authors:  R Mandrell; H Schneider; M Apicella; W Zollinger; P A Rice; J M Griffiss
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

3.  Serum killing of meningococci and several other gram-negative bacterial species is not decreased by incubating them with cytidine 5'-monophospho-N-acetyl neuraminic acid.

Authors:  A J Fox; D M Jones; S M Scotland; B Rowe; A Smith; M R Brown; R G Fitzgeorge; A Baskerville; N J Parsons; J A Cole
Journal:  Microb Pathog       Date:  1989-10       Impact factor: 3.738

4.  The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.

Authors:  E Rosenqvist; E A Høiby; E Wedege; B Kusecek; M Achtman
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

5.  The sialylation of gonococcal lipopolysaccharide by host factors: a major impact on pathogenicity.

Authors:  H Smith; J A Cole; N J Parsons
Journal:  FEMS Microbiol Lett       Date:  1992-12-15       Impact factor: 2.742

6.  Structure and immunochemistry of meningococcal lipopolysaccharides.

Authors:  H J Jennings; M Beurret; A Gamian; F Michon
Journal:  Antonie Van Leeuwenhoek       Date:  1987       Impact factor: 2.271

7.  Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis.

Authors:  J J Kim; R E Mandrell; Z Hu; M A Westerink; J T Poolman; J M Griffiss
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

8.  Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection.

Authors:  C R Tinsley; J E Heckels
Journal:  J Gen Microbiol       Date:  1986-09

9.  Instability of expression of lipooligosaccharides and their epitopes in Neisseria gonorrhoeae.

Authors:  H Schneider; C A Hammack; M A Apicella; J M Griffiss
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

10.  Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A.

Authors:  M Achtman; M Neibert; B A Crowe; W Strittmatter; B Kusecek; E Weyse; M J Walsh; B Slawig; G Morelli; A Moll
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

View more
  30 in total

1.  Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.

Authors:  E Rosenqvist; A Musacchio; A Aase; E A Høiby; E Namork; J Kolberg; E Wedege; A Delvig; R Dalseg; T E Michaelsen; J Tommassen
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

2.  Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Authors:  Rohit K Katial; Brenda L Brandt; Ellen E Moran; Stephen Marks; Victor Agnello; Wendell D Zollinger
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 3.  Phase and antigenic variation in bacteria.

Authors:  Marjan W van der Woude; Andreas J Bäumler
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

4.  Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.

Authors:  Makda Fisseha; Ping Chen; Brenda Brandt; Todd Kijek; Elizabeth Moran; Wendell Zollinger
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.

Authors:  Wendell D Zollinger; Elizabeth E Moran; Deborah H Schmiel
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

6.  Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; E E Moran; T Larsen; W D Zollinger
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

7.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

8.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

9.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.

Authors:  C M Kahler; L E Martin; G C Shih; M M Rahman; R W Carlson; D S Stephens
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.